Your session is about to expire
← Back to Search
Gabapentin for Bipolar Disorder
Study Summary
This trial will study the effects of Gabapentin on people with Bipolar Disorder who use marijuana. They will take the medication or a placebo for 17 days, and have 5 study visits with 2 MRI brain scans.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2021 Phase 4 trial • 88 Patients • NCT03012815Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I take a daily mood stabilizer like lithium or lamotrigine.I am not pregnant, breastfeeding, and I use effective birth control.My kidney function is low, with creatinine levels more than double the normal range.I am not taking opioids, benzodiazepines, barbiturates, or similar medications.I am not taking Azelastine, Orphenadrine, Oxomemazine, Paraldehyde, or Thalidomide with Gabapentin.I am between 18 and 65 years old.I have taken gabapentin recently or had a bad reaction to it.I have a significant problem with cannabis use, tested positive for it, and it's my main substance issue.I have not had mental retardation, dementia, or electroconvulsive therapy recently.My liver enzymes are more than three times the normal level.I am not taking medications that affect brain signaling, like benzodiazepines or ketamine.I do not have any uncontrolled neurological conditions like epilepsy.I am willing to follow the treatment and check-up plan.I have had a brain injury where I was unconscious for more than 5 minutes.
- Group 1: Group A - Gabapentin
- Group 2: Group B - Placebo
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How widespread is the participation in this research project?
"Affirmative. The information posted on clinicaltrials.gov reveals that this medical trial, which was initially published on February 24th 2022 is currently seeking volunteers. Approximately 68 participants need to be enlisted from a single site."
Is this medical experiment open to elderly individuals?
"This research trial adheres to strict age requirements, demanding that potential participants must be 18 or above and 65 or below."
Are there any other research initiatives that have studied the effects of Gabapentin?
"Currently, 25 studies are underway for the evaluation of Gabapentin's efficacy with 9 trials in their final phase. These clinical research sites span 67 different locations across the country but many have chosen to conduct their study in Columbus, Ohio."
To what type of ailments does Gabapentin offer symptomatic relief?
"Gabapentin can be leveraged to alleviate the symptoms of neuralgia, epilepsies and postherpetic neuralgia."
Is registration for this experiment still open to participants?
"Affirmative. Clinicaltrials.gov stipulates that this trial, which was initially posted on February 24th 2022, is actively enrolling participants in need of treatment. 68 volunteers are needed from 1 medical institution."
What risks come with taking Gabapentin on a regular basis?
"Based on available evidence, Gabapentin has been estimated to have a safety score of 2. This is due to its Phase 2 status, indicating that there are reports supporting the drug's safety yet no backing for efficacy."
Am I eligible to sign up for participation in this research?
"The requirements for admission to this trial are a manic disorder diagnosis and an age between 18 and 65. Space is limited, with only 68 spots available in total."
Who else is applying?
What state do they live in?
How old are they?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger